Where does Nagasaki University rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Nagasaki University ranks #10,107 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Nagasaki University hold?

Nagasaki University holds 31 US utility patents granted between 2015 and 2025, spanning 33 technology areas.

What is Nagasaki University's Innovation Score?

Nagasaki University has an Innovation Score of 42.3 out of 100 (top 31% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Nagasaki University focus on?

Nagasaki University's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 14 patents, ranking #1,384 of 6,058 assignees active in that subclass. Grants appear in 33 CPC subclasses total.

Is Nagasaki University's patent grant rate increasing or decreasing?

Nagasaki University's recent grant velocity is -62% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Nagasaki University's patents?

Nagasaki University's patents average 10.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Nagasaki University patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Nagasaki University

USPTO PatentsView assignee record - 31 granted patents across 33 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Nagasaki ranks #10,107 of 49,997 tracked US assignees by granted-patent volume, with 31 patents across 33 technology areas.

#10,107
of 49,997 US assignees by volume: Top 31%
by Innovation Score (42.3/100): 10.4
avg claims per patent: -62%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R10107 · Foreign Corporation #10,107 · 31 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 31 grants
UPPER-Q #10,107/49,997
PHOTO-FINISH Natco Pharma
CPC-FOCUS A61P · 33 areas
INNOV-PAR 42.3/100
CLAIMS-PAR 10.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -62% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Natco Pharma Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Nagasaki’s 42.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.0 pts (28%) Velocity 3.8 pts (9%) Breadth 20.3 pts (48%) Claim depth 6.3 pts (15%)

Qualcomm Incorporated · highest

85
QSC · near

42
Erasmus University… · near

42
Invoy Holdings · near

42
Nagasaki University · this assignee

42
SAP Portals Israel · near

42
3D Lighting… · lowest

7

What this shows Nagasaki's Innovation Score is 42.3/100 (top 31% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Nagasaki?

Each dot is one of Nagasaki’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Nagasaki’s own 10.4 claims/patent is at or below the 15.8 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Nagasaki vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Nagasaki's grants concentrate

Nagasaki University is a focused PatentsView assignee: 33 CPC subclasses with 45.2% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (5 grants) versus a trough of 1 in 2021. By volume, Nagasaki sits between Natco Pharma Limited and Neptune Technology Group LLC.

Nagasaki's three-year grant acceleration

Nagasaki University shows 4 grants in 2022–2024 against only 7 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Natco Pharma

31
Nissin Electric

31
Noble Internation…

31
Northgate

31
National Service…

31
National Universi…

31
Nativo

31
Neptune Technolog…

31
Nagasaki Universi… ◀

31

What this shows Nagasaki holds 31 patents at rank #10,112, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Nagasaki

By rank, the assignees closest to #10,112 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Nagasaki's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Nagasaki, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Nagasaki ranks #1,384 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (42 here).

Invoy Holdings Inc. 42 Erasmus University Medical Center Rotterdam 42 SAP Portals Israel Ltd 42 QSC, LLC 42

Nagasaki's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 31% higher than 69% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Nagasaki University patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	5	16.1%
2016	4	12.9%
2017	5	16.1%
2018	4	12.9%
2019	3	9.7%
2020	3	9.7%
2021	1	3.2%
2022	3	9.7%
2023	1	3.2%
2025partial year	2	6.5%

Which technologies does Nagasaki University patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 14

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 13

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 8

C07K - Peptides 5

C07D - Heterocyclic Compounds 5

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 4

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

H02M - Apparatus FOR Conversion Between AC AND AC, Between AC AND DC, OR Between DC AND DC, AND FOR USE With Mains OR Similar Power Supply SYSTEMS; Conversion OF DC OR AC Input Power Into Surge Output POWER; Control OR Regulation Thereof 3

Y02A - Technologies FOR Adaptation TO Climate Change 2

A61B - DIAGNOSIS; SURGERY; Identification 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

Y02B - Climate Change Mitigation Technologies Related TO Buildings, e.g. Housing, House Appliances OR Related End-user Applications 2

C12Y - Enzymes 2

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

Top 15 of 33 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Nagasaki University's patent record in context - here's where to go next.

Nagasaki University's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 45.2% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #10,107 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Nagasaki University against Natco Pharma Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 42.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.